Cargando…

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry

BACKGROUND: The clinical practice of stroke prevention in atrial fibrillation (AF) with direct oral anticoagulants (DOACS) differs from anticoagulation in randomized trial patients. We investigated the risk of thromboembolism, bleeding, and drug discontinuation in a hospital-based real-world setting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Königsbrügge, Oliver, Simon, Alexander, Domanovits, Hans, Pabinger, Ingrid, Ay, Cihan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148877/ https://www.ncbi.nlm.nih.gov/pubmed/27938343 http://dx.doi.org/10.1186/s12872-016-0438-5

Ejemplares similares

Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study
por: Steiner, Daniel, et al.
Publicado: (2022)

Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
por: Königsbrügge, Oliver, et al.
Publicado: (2019)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
por: Nopp, Stephan, et al.
Publicado: (2023)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
por: Vene, Nina, et al.
Publicado: (2016)

Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation
por: Hellfritzsch, Maja, et al.
Publicado: (2017)

Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital
por: Nopp, Stephan, et al.
Publicado: (2020)

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
por: Magnocavallo, Michele, et al.
Publicado: (2020)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2021)

Oral Anticoagulant Discontinuation and Its Predictors in Patients with Atrial Fibrillation
por: Kefale, Adane Teshome, et al.
Publicado: (2022)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
por: Mehic, Dino, et al.
Publicado: (2023)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
por: Henz, Benhur Davi, et al.
Publicado: (2018)

Thromboembolic Events in Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation During New Oral Anticoagulant Therapy
por: An, Myeonghyun, et al.
Publicado: (2023)

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry
por: Cools, Frank, et al.
Publicado: (2021)

Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation
por: Matos, Jason D., et al.
Publicado: (2018)

Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry
por: Okumura, Ken, et al.
Publicado: (2022)

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation
por: Takahashi, Masahiko, et al.
Publicado: (2023)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
por: Ballestri, Stefano, et al.
Publicado: (2022)

Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes
por: Winkle, Roger A., et al.
Publicado: (2013)

Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review
por: Buck, Jackie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2q56v9apojitnvf1siqfrorej3